Revolution Medicines (RVMD) Stock Price, News & Analysis

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 1 year price objectives for Revolution Medicines' shares. Their RVMD share price targets range from $28.00 to $48.00. On average, they anticipate the company's share price to reach $41.20 in the next year. This suggests a possible upside of 15.0% from the stock's current price.
View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts.

Revolution Medicines' stock was trading at $28.68 on January 1st, 2024. Since then, RVMD shares have increased by 24.9% and is now trading at $35.83.
View the best growth stocks for 2024 here.

Revolution Medicines saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 12,000,000 shares, a drop of 26.8% from the March 15th total of 16,400,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is currently 8.9 days.
View Revolution Medicines' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our RVMD earnings forecast.

Revolution Medicines, Inc. (NASDAQ:RVMD) posted its earnings results on Monday, February, 26th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.29. The business had revenue of $0.74 million for the quarter, compared to analyst estimates of $1.20 million. The company's revenue was down 95.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.63) earnings per share.

ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), Harbor Health Care ETF (MEDI) and JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

Revolution Medicines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Mass General Brigham Inc (0.21%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Sushil Patel, Thilo Schroeder and Xiaolin Wang.
View institutional ownership trends.

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.